Filing Details
- Accession Number:
- 0001415889-24-003637
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-13 19:34:59
- Reporting Period:
- 2021-08-16
- Accepted Time:
- 2024-02-13 19:34:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787297 | Passage Bio Inc. | PASG | Biological Products, (No Disgnostic Substances) (2836) | 822729751 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1922353 | S Mark Forman | One Commerce Square 2005 Market Street, 39Th Floor Philadelphia PA 19103 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-10 | 5,000 | $0.00 | 50,269 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-13 | 1,638 | $0.97 | 48,631 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Acquisiton | 2021-08-16 | 130,000 | $0.00 | 130,000 | $10.84 |
| Common Stock | Employee Stock Option (right to buy) | Acquisiton | 2022-02-10 | 25,000 | $0.00 | 25,000 | $4.52 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2022-02-10 | 15,000 | $0.00 | 15,000 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2024-02-10 | 5,000 | $0.00 | 5,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 130,000 | 2031-08-15 | No | 4 | A | Direct | |
| 25,000 | 2032-02-09 | No | 4 | A | Direct | |
| 15,000 | No | 4 | A | Direct | ||
| 10,000 | No | 4 | M | Direct |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Billionaire Hedge Funds
